ISO 9001:2015 Certified
Live Customer Support
4.5/5 on Trustpilot
100% Quality Guarantee

Cofetuzumab Biosimilar - Anti-CCK4 Antibody - Low endotoxin, Azide free (A323366)

Recombinant humanized monoclonal antibody to CCK4 for ELISA, FACS, Functional Assay and In Vivo.

Shipping Information

$40
Dispatched from St. Louis, MO.
Lead Time: 12-18 business days.
Name
Cofetuzumab Biosimilar - Anti-CCK4 Antibody - Low endotoxin, Azide free
Description
Recombinant humanized monoclonal antibody to CCK4.
Applications
ELISA, FACS, Functional Assay, In Vivo
Reactivity
Human, Mouse, Cynomolgus Macaque
Host
Humanized
Clonality
Monoclonal
Isotype
IgG1
Light Chains
kappa
Conjugate

Unconjugated

Purification
Protein A affinity chromatography.
Concentration
Reconstitution dependent.
Molecular Weight
This antibody has a predicted MW of 145 kDa.
Purity
> 95% (by SDS-PAGE and SEC-HPLC).
Product Form
Lyophilized
Reconstitution
Reconstitute with 100µl of sterile double-distilled water to bring antibody to 1mg/ml concentration. Gently shake to solubilize completely. Do not vortex!
Formulation
Lyophilized from 25mM Histadine, pH 6.2, with 8% Sucrose and 0.01% Tween80.
Storage
Shipped at 4°C. Lyophilized: Store at -20°C to -80°C. Reconstituted: Aliquot and store at -80°C. Product is stable for one year. Avoid freeze/thaw cycles.
Synonyms
CCK-4, Colon carcinoma kinase 4, Inactive tyrosine-protein kinase 7, Protein-tyrosine kinase 7, Pseudo tyrosine kinase receptor 7, PTK7, Tyrosine-protein kinase-like 7
Disclaimer
This product is for research use only. It is not intended for diagnostic or therapeutic use.
Publishing research using Cofetuzumab Biosimilar - Anti-CCK4 Antibody - Low endotoxin, Azide free (A323366)? Please let us know so that we can list the citation on this page.

Alternative products to Cofetuzumab Biosimilar - Anti-CCK4 Antibody - Low endotoxin, Azide free (A323366)

Proteins predicted to interact with CCK4

Predicted protein interactions based upon String database. Revelancy score correlates with probability of interaction.
98.3% Relevancy Score
95.2% Relevancy Score
93.7% Relevancy Score
92.3% Relevancy Score
89.1% Relevancy Score
88.2% Relevancy Score
87.9% Relevancy Score
86.9% Relevancy Score
82.4% Relevancy Score